1. Scrip
  2. >>Conferences
  3. >>BIO

Sutro Works Toward A Better Ovarian Cancer ADC

Readies Next Asset For The Clinic

 
• By Mandy Jackson

Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.

Sutro Biopharma sign, logo on headquarters facade of an American public biotechnology company. - South San Francisco, California,
• Source: Shutterstock

Sutro Biopharma, Inc. chose to focus its cell-free protein synthesis technology platform on antibody-drug conjugates (ADCs) long before ADCs were elevated to high-value status in recent years, and the company has used business development strategically to raise funding for its wholly owned development programs and to advance its XpressCF platform. Now, its lead ADC candidate luveltamab tazevibulin (luvelta) is in a pivotal trial to see if Sutro can deliver a better ovarian cancer option.

Key Takeaways

  • Sutro has taken lead product candidate luvelta into a pivotal trial in ovarian cancer in an increasingly competitive space – FRα-targeting ADCs.

Scrip spoke with CEO Bill Newell at the recent BIO International Convention about luvelta’s ongoing Phase II/III REFRαME-01 clinical trial,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from BIO

AI Is Inevitable, But Useful Only If Solves The Right Problems

 
• By Mandy Jackson

Scrip spoke with executives at artificial intelligence biotech firms and a big pharma company during the recent BIO conference about using AI in ways that add real value to drug development.

BIO China Deal Perspectives: A Dramatic Impact On Industry’s R&D Pipelines

 
• By Mandy Jackson

Biopharma executives and investors at the BIO convention noted the competition emerging from China with high-quality assets that could make strong additions to their portfolios.

BIO Finance Trends: Drug Developers Face Harsh Realities As Funding Constraints Continue

 
• By Mandy Jackson

Financial markets were expected to loosen up in 2025, but BIO convention attendees indicated that conditions have worsened this year, so public and private firms are making tough choices.

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.

More from Conferences

Jefferies 25: Biotech Leaders Bullish As M&A Heats Up

 
• By Andrew McConaghie

A rush of bigger M&A deals is inspiring renewed confidence in the biotech sector, but US companies are facing up to unprecedented competition from China.

Clinicians Weigh In On Evolution Of MASH Treatment

 
• By Joseph Haas

With Novo Nordisk’s Wegovy joining Madrigal’s Rezdiffra as an FDA-approved MASH treatment, doctors now can choose between direct liver benefits or pursuing weight loss.

Jefferies Conference 2025: Five Themes To Follow

 
• By Andrew McConaghie

The investor event will bring deal-hungry big pharma and biotech execs together but input from the FDA’s unsettled leadership will be missing this year.